Skip to main content
padlock icon - secure page this page is secure

Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab

Buy Article:

$59.00 + tax (Refund Policy)

Kyrtsonis M-C, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Abstract: 

Primary cutaneous marginal zone lymphoma (PCMZL) is an indolent disease. Treatment options include excision, local irradiation, interferon-α or chemotherapy. We present two patients with PCMZL and multiple skin lesions successfully treated with intralesional administration of the anti-CD20 monoclonal antibody rituximab. The first presented with four red skin lesions and the second with two. Biopsy of the largest lesion revealed marginal zone B-cell lymphoma in both patients. There was no evidence of systemic involvement in either patient. Both patients were treated with intralesional rituximab for 18 consecutive weeks. Skin lesions gradually regressed. Apart from mild local pain during the injection, no other adverse effects were observed. In conclusion, rituximab can be safely administered intralesionally in patients with PCMZL and can produce disease remission.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: intralesional; marginal zone lymphoma; primary cutaneous; rituximab; topical

Document Type: Research Article

Publication date: October 1, 2006

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more